December 10, 2010 – bioTheranostics, a bioMérieux company that develops innovative oncology diagnostic tests to support targeted disease management, announced new findings from a clinical study evaluating the company’s Breast Cancer Index (BCI) molecular oncology test. Data from the study were presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).The company also announced that the Breast Cancer Index is now available to provide quantitative assessment of the risk of distant disease recurrence. The BCI risk assessment is based on data from a recently completed large, randomized, retrospective trial.
“The results presented in San Antonio today become part of a substantial and growing body of data supporting the clinical value of the Breast Cancer Index,” said Richard Ding, chief executive officer of bioTheranostics. “We are pleased to make this valuable test available to oncologists and pathologists in an enhanced format with clinical data specific for late breast cancer recurrence.”...
[...]
...About bioTheranostics
Advancing Molecular Diagnostics in Oncology
bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community to support targeted disease management. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: Breast Cancer Index, which provides risk stratification in patients with estrogen receptor (ER)-positive, lymph-node negative breast cancer; and the CancerTYPE IDâ test, a cancer classification assay that provides molecular classification of cancers with indeterminate, uncertain, or differential diagnoses to aid in the determination of the tumor site of origin... bioTheranostics' Press Release -
